Cargando…

A multimodality imaging model to track viable breast cancer cells from single arrest to metastasis in the mouse brain

Cellular MRI involves sensitive visualization of iron-labeled cells in vivo but cannot differentiate between dead and viable cells. Bioluminescence imaging (BLI) measures cellular viability, and thus we explored combining these tools to provide a more holistic view of metastatic cancer cell fate in...

Descripción completa

Detalles Bibliográficos
Autores principales: Parkins, Katie M., Hamilton, Amanda M., Makela, Ashley V., Chen, Yuanxin, Foster, Paula J., Ronald, John A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5073295/
https://www.ncbi.nlm.nih.gov/pubmed/27767185
http://dx.doi.org/10.1038/srep35889
_version_ 1782461544670429184
author Parkins, Katie M.
Hamilton, Amanda M.
Makela, Ashley V.
Chen, Yuanxin
Foster, Paula J.
Ronald, John A.
author_facet Parkins, Katie M.
Hamilton, Amanda M.
Makela, Ashley V.
Chen, Yuanxin
Foster, Paula J.
Ronald, John A.
author_sort Parkins, Katie M.
collection PubMed
description Cellular MRI involves sensitive visualization of iron-labeled cells in vivo but cannot differentiate between dead and viable cells. Bioluminescence imaging (BLI) measures cellular viability, and thus we explored combining these tools to provide a more holistic view of metastatic cancer cell fate in mice. Human breast carcinoma cells stably expressing Firefly luciferase were loaded with iron particles, injected into the left ventricle, and BLI and MRI were performed on days 0, 8, 21 and 28. The number of brain MR signal voids (i.e., iron-loaded cells) on day 0 significantly correlated with BLI signal. Both BLI and MRI signals decreased from day 0 to day 8, indicating a loss of viable cells rather than a loss of iron label. Total brain MR tumour volume on day 28 also correlated with BLI signal. Overall, BLI complemented our sensitive cellular MRI technologies well, allowing us for the first time to screen animals for successful injections, and, in addition to MR measures of cell arrest and tumor burden, provided longitudinal measures of cancer cell viability in individual animals. We predict this novel multimodality molecular imaging framework will be useful for evaluating the efficacy of emerging anti-cancer drugs at different stages of the metastatic cascade.
format Online
Article
Text
id pubmed-5073295
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-50732952016-10-26 A multimodality imaging model to track viable breast cancer cells from single arrest to metastasis in the mouse brain Parkins, Katie M. Hamilton, Amanda M. Makela, Ashley V. Chen, Yuanxin Foster, Paula J. Ronald, John A. Sci Rep Article Cellular MRI involves sensitive visualization of iron-labeled cells in vivo but cannot differentiate between dead and viable cells. Bioluminescence imaging (BLI) measures cellular viability, and thus we explored combining these tools to provide a more holistic view of metastatic cancer cell fate in mice. Human breast carcinoma cells stably expressing Firefly luciferase were loaded with iron particles, injected into the left ventricle, and BLI and MRI were performed on days 0, 8, 21 and 28. The number of brain MR signal voids (i.e., iron-loaded cells) on day 0 significantly correlated with BLI signal. Both BLI and MRI signals decreased from day 0 to day 8, indicating a loss of viable cells rather than a loss of iron label. Total brain MR tumour volume on day 28 also correlated with BLI signal. Overall, BLI complemented our sensitive cellular MRI technologies well, allowing us for the first time to screen animals for successful injections, and, in addition to MR measures of cell arrest and tumor burden, provided longitudinal measures of cancer cell viability in individual animals. We predict this novel multimodality molecular imaging framework will be useful for evaluating the efficacy of emerging anti-cancer drugs at different stages of the metastatic cascade. Nature Publishing Group 2016-10-21 /pmc/articles/PMC5073295/ /pubmed/27767185 http://dx.doi.org/10.1038/srep35889 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Parkins, Katie M.
Hamilton, Amanda M.
Makela, Ashley V.
Chen, Yuanxin
Foster, Paula J.
Ronald, John A.
A multimodality imaging model to track viable breast cancer cells from single arrest to metastasis in the mouse brain
title A multimodality imaging model to track viable breast cancer cells from single arrest to metastasis in the mouse brain
title_full A multimodality imaging model to track viable breast cancer cells from single arrest to metastasis in the mouse brain
title_fullStr A multimodality imaging model to track viable breast cancer cells from single arrest to metastasis in the mouse brain
title_full_unstemmed A multimodality imaging model to track viable breast cancer cells from single arrest to metastasis in the mouse brain
title_short A multimodality imaging model to track viable breast cancer cells from single arrest to metastasis in the mouse brain
title_sort multimodality imaging model to track viable breast cancer cells from single arrest to metastasis in the mouse brain
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5073295/
https://www.ncbi.nlm.nih.gov/pubmed/27767185
http://dx.doi.org/10.1038/srep35889
work_keys_str_mv AT parkinskatiem amultimodalityimagingmodeltotrackviablebreastcancercellsfromsinglearresttometastasisinthemousebrain
AT hamiltonamandam amultimodalityimagingmodeltotrackviablebreastcancercellsfromsinglearresttometastasisinthemousebrain
AT makelaashleyv amultimodalityimagingmodeltotrackviablebreastcancercellsfromsinglearresttometastasisinthemousebrain
AT chenyuanxin amultimodalityimagingmodeltotrackviablebreastcancercellsfromsinglearresttometastasisinthemousebrain
AT fosterpaulaj amultimodalityimagingmodeltotrackviablebreastcancercellsfromsinglearresttometastasisinthemousebrain
AT ronaldjohna amultimodalityimagingmodeltotrackviablebreastcancercellsfromsinglearresttometastasisinthemousebrain
AT parkinskatiem multimodalityimagingmodeltotrackviablebreastcancercellsfromsinglearresttometastasisinthemousebrain
AT hamiltonamandam multimodalityimagingmodeltotrackviablebreastcancercellsfromsinglearresttometastasisinthemousebrain
AT makelaashleyv multimodalityimagingmodeltotrackviablebreastcancercellsfromsinglearresttometastasisinthemousebrain
AT chenyuanxin multimodalityimagingmodeltotrackviablebreastcancercellsfromsinglearresttometastasisinthemousebrain
AT fosterpaulaj multimodalityimagingmodeltotrackviablebreastcancercellsfromsinglearresttometastasisinthemousebrain
AT ronaldjohna multimodalityimagingmodeltotrackviablebreastcancercellsfromsinglearresttometastasisinthemousebrain